BRCA1 and ovarian carcinoma: However, oestrogen, acting via the PI3K/Akt pathway in breast and ovarian cancer cells, can stimulate NRF2 in BRCA1-deficient cells and help sustain these cells which increase their genomic instability eventually leading to malignancy[210].